Clinical Trial Update: Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating controllable PRAME-TCR therapy in patients with acute myeloid leukemia, myelodysplastic syndrome, or metastatic uveal melanoma has te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Uveal Melanoma

Drugs mentioned

• PRAME-TCR therapy (controllable) (PRAME-targeted T-cell receptor therapy)

Snippet

Sponsor: Bellicum Pharmaceuticals | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-10-05